ClinicalTrials.gg
RecruitingNCT06259890SALTUpdated Jul 9, 2025

Influence of Sodium Intake in spondyLoarthriTes

An interventional study of measurement of salt intake in Spondyloarthritis, Axial and Arthritis, Psoriatic, sponsored by Centre Hospitalier Universitaire de Besancon. Recruiting at 4 sites in France. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-07-09.

Sponsored by Centre Hospitalier Universitaire de Besancon · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Jan 2024; still recruiting 2 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
250
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 40 studies in Axial Spondyloarthritis with a site in France — 9 open to participants now, 11 under way, 3 of them phase 3. Axial Spondyloarthritis · France.

Planned enrollment
14th of 30
250 · median 188
Started
2024
with 3 others
No phase
13 of 40
6 open now
Primary completion
2026-11
later than 3 of 10 live
Registered
38th of 40
by date
Lead sponsor
4 of 40
Centre Hospitalier Universitaire de Besancon

Among the 40 studies in Axial Spondyloarthritis with a site in France, this one is the 14th largest by planned enrollment of the 30 interventional ones that give a count, is one of 4 that started in 2024, is one of 13 with no phase, reaches primary completion later than 3 of the 10 other live ones, and was the 38th registered.

Axial Spondyloarthritis

187 studies on the registry are indexed under Axial Spondyloarthritis; 57 are open to participants now.

Browse Axial Spondyloarthritis studies →

Open to participants now

9 of the 40 studies in Axial Spondyloarthritis with a site in France are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 39 Axial Spondyloarthritis studies recruiting now, 20 (51%) set no upper age limit and 13 (33%) stop at 75 or younger; 5 take children under 18; 3 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Axial Spondyloarthritis with a site in France, or all of them as a file.
02

Study summary

The aim of the SALT study is to analyze the relationship between dietary sodium intake and disease activity in patients with axial spondyloarthritis (radiographic or non-radiographic) or psoriatic arthritis.

03

Conditions studied

  • Spondyloarthritis, Axial
  • Arthritis, Psoriatic

Keywords

  • Sodium intake
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patients with axial spondyloarthritis (radiographic or non-radiographic) or psoriatic arthritis
  • women who have been menopausal for at least 24 months, surgically sterilized, or, for women of childbearing potentiale, use an effective method of (oral contraceptives, contraceptive injections, intrauterine devices, double-barrier method, contraceptive patches)

Exclusion criteria

Exclusion Criteria:

  • patient treated by cyclosporine, diuretics, angiotensin-converting enzyme inhibitors or angiotensin II receptor antagonists.
  • current treatment with an anti-IL-17A agent (secukinumab or ixekizumab or bimekizumab or brodalumab) or with an anti-IL23 agent (ustekinumab, guselkumab, risankizumab or tildrakizumab) or previous treatment less than 6 months old.
  • patients on systemic with corticosteroid therapy > 10 mg prednisone equivalent
  • pregnant woman
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
250 participants (estimated)

Study arms

  • Other
    Patients with radiographic/non-radiographic Axial Spondylitis or psoriatic arthritis

    Patients with radiographic/non-radiographic Axial Spondylitis or psoriatic arthritis managed in the rheumatology departments of the study centres.

    Other: measurement of salt intake

Interventions

  • Othermeasurement of salt intake

    measurement of salt intake without intervention

06

What researchers measure

Primary outcomes

  1. sodium intake

    average sodium concentration in urine for the week

    Time frame: day of inclusion, monday and tuesday following

07

Study locations

4 of 4 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Nov 2026, 34 months after the start.

Of 46 non-industry interventional studies with no phase under Axial Spondyloarthritis, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 42. This study's planned 34 months is above that.

Counting every sponsor, half of 46 studies reached it within 28 months; a quarter within 11 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 31, 2024
First posted
Feb 14, 2024
StartActual
Jan 30, 2024
Primary completionEst.
Nov 2026
CompletionEst.
May 2027
Last update
Jul 9, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06259890
Collaborators
French Society of Rheumatology
Responsible party
Sponsor
First posted
Feb 14, 2024
Start date
Jan 30, 2024
Primary completion
Nov 2026 (estimated)
Completion
May 2027 (estimated)
Last update
Jul 9, 2025

Study contacts

Guillaume BOITEUX, PhD
Contact
gboiteux@chu-besancon.fr
+33381218957
Elise Robert
Contact
e1robert@chu-besancon.fr
0381219086

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion